Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib + Chemotherapy + Bevacizumab as Perioperative Therapy in Resectable Stage IIb–IIIb EGFR-Mutant NSCLC
ChiCTR2500107744Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of icotinib in EGFR-mutated non-small cell lung cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoint: Major pathological response (MPR). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
icotinib
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2500107744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107744.